Stroquinan

Drug Profile

Stroquinan

Alternative Names: SP-8203; SP-8203 hydrochloride; SP8203HCL

Latest Information Update: 07 Jun 2016

Price : $50

At a glance

  • Originator Shin Poong Pharmaceutical
  • Class Neuroprotectants; Quinazolines
  • Mechanism of Action Reactive oxygen species inhibitors; Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 May 2016 Phase-II clinical trials in Stroke (Adjunctive treatment) in South Korea (IV) (NCT02787278)
  • 28 Dec 2012 Shin Poong Pharmaceutical plans a phase I trial in Healthy volunteers in South Korea (NCT01757795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top